Cambridge Biotech Corp. on Wednesday said it has signed adefinitive agreement with Virbac Laboratories SA to develop arecombinant vaccine against feline immunodeficiency virus(FIV), a retrovirus that affects cats.
Virbac of Carrons Cedex, France, will fund the development ofthe vaccine. No other terms were disclosed.
No vaccine exists for FIV, which infects from 1 percent to 3percent of the 55 million cats in the United States.
This is the second agreement between Cambridge and Virbac.The companies have developed a vaccine for feline leukemiavirus (FeLV), which went on the market in France andSwitzerland in 1989 and in the United States in 1990.
Cambridge (NASDAQ:CBCX) estimated it will gross $2 millionto $3 million from FeLV in 1991. It estimated an eventualworld market of $50 million to $75 million.
(c) 1997 American Health Consultants. All rights reserved.